^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1370P - PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)
Published date:
09/14/2020
Excerpt:
Twelve trials were identified, involving 4031 patients with EGFR/ALK wild type tumors…Chemotherapy consisted of a cisplatin/carboplatin backbone with pemetrexed/gemcitabine/nab-paclitaxel...High PD-L1 expression is associated with improved ORR with platinum doublet chemotherapy in mNSCLC.
